Nora Be Tablet
Product Images NDC 0480-3475

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Nora Be (NDC 0480-3475). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Norethindrone Structural Formula. (Nora Be N017060 1)

Chemical structure of Norethindrone, the active ingredient in Nora BE 0.35 mg oral tablets by Teva Pharmaceuticals. The diagram depicts the steroid backbone with functional groups including a hydroxyl group and an alkyne moiety.*

FDA Label Image

Figure 1 (Nora Be N017060 2)

Pharmacokinetic curve showing plasma concentration (Cp in pg/mL) of Norethindrone over time (hours) following a 0.35 mg oral dose. The graph displays a sharp peak in concentration within the first few hours, followed by a gradual decline to near zero by 48 hours post-dose.*

FDA Label Image

Carton Image (Nora Be N017060 3)

Packaging label for Nora-BE 0.35 mg tablets containing Norethindrone, oral tablets distributed by Teva Pharmaceuticals. The label indicates 6 tablet dispensers with 28 tablets each, prescription-only status, and includes storage instructions and a note to dispensers regarding patient labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.